Advertisement

Topics

Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure

2014-07-23 21:12:36 | BioPortfolio

Summary

The purpose of this study is to determine whether the treatment strategy of long-term intermittent every 30 days, continuous intravenous infusion for 24 hours of Levosimendan, associated to optimal contemporary treatment for advanced heart failure reduce the incidence of admission for heart failure worsening at 12 months follow up, compared with the strategy based solely in the optimal contemporary treatment for advanced heart failure.

Description

Aims: To evaluate the efficacy and safety of long-term, intermittent intravenous administration for 24 hours of Levosimendan for the treatment of advanced heart failure. Main end-point: incidence of admission due to decompensation, defined as first admission to emergency services or hospitalization more than 12 hours due to heart failure worsening.

Secondary end-points: major cardiac events, serious adverse events, change in NYHA scale at baseline, 30 days, 6 and 12 months; effects on inflammatory and neurohormonal activation in heart failure, identify factors associated with better survival of patients, quality of life, cost-effectiveness of treatment.

Study Design: Prospective, randomized, double-blind placebo controlled trial.

Scope of the study: patients with advanced heart failure.

Study Subjects: Patients over 18 years old with advanced HF of any etiology, with at least one admission for acute decompensation treated or treatable with Levosimendan within 6 months prior to randomization.

Interventions: a 24-hour infusion every 30 days of Levosimendan or placebo in addition to optimal pharmacological treatment for HF during 12 months.

Determinations: clinical monitoring, protocol-specified analytical determinations, echocardiographic assessment, invasive hemodynamic assessment, functional assessment by 6 min walk test in corridor, quality of life assessment at baseline, after 30 days, 6 months and 12 months.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Conditions

Advanced Heart Failure

Intervention

Levosimendan, Placebo

Location

Department of Cardiology. Hospital Universitario de Canarias
La Laguna
S.C. de Tenerife
Spain
38320

Status

Enrolling by invitation

Source

Hospital Universitario de Canarias

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:12:36-0400

Clinical Trials [2849 Associated Clinical Trials listed on BioPortfolio]

Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure

Repetitive levosimendan infusions for patients with advanced chronic heart failure (LeoDOR) A randomised, double-blind, placebo-controlled multicentre study with parallel group design. Mo...

Effect of Levosimendan or Placebo on Exercise in Advanced Chronic Heart Failure

Purpose: This study evaluates the subacute effect of levosimendan infusion on exercise capacity and exercise hemodynamics compared with placebo in patients with advanced chronic heart fail...

Levosimendan in High Risk Heart Valve Surgery

Prospective, randomized, double blind study investigating the efficacy of levosimendan in heart failure after cardiac surgery. Study hypothesis: Levosimendan diminishes the need for adren...

Levosimendan Pharmacokinetics in Children

Levosimendan is a drug used in patients with heart failure and has several advantages over other heart failure drugs. A lot of research has been done with Levosimendan in Adults, and the w...

Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure

Open label study of levosimendan; planned comparison for effectiveness and safety to historic matched case controls from participating sites.

PubMed Articles [10900 Associated PubMed Articles listed on BioPortfolio]

Effect of levosimendan in patients with acute decompensated heart failure : A meta-analysis.

Acute decompensated heart failure (ADHF) is associated with high morbidity and mortality. Intravenous inotropic agents play an important role in treating ADHF. Relatively small clinical studies have e...

Correction to: 2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant): A Report of the ACC Competency Management Committee.

Low frequency electrical muscle stimulation and endothelial function in advanced heart failure patients.

Obtain initial estimates of the change in brachial artery endothelial function and maximal oxygen uptake (VO ) with 8 weeks of low-frequency electrical muscle stimulation (LF-EMS) or sham in patients...

Empagliflozin directly improves diastolic function in human heart failure.

Empagliflozin, a clinically used oral antidiabetic drug that inhibits the sodium-dependent glucose co-transporter 2, has recently been evaluated for its cardiovascular safety. Surprisingly, empagliflo...

EXPRESS: Levosimendan in Pulmonary Hypertension and Right Heart Failure.

Medical and Biotech [MESH] Definitions

A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.

Heart failure caused by abnormal myocardial relaxation during DIASTOLE leading to defective cardiac filling.

Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).

More From BioPortfolio on "Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial